Investor Baker Julian
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Baker Julian . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2017-02-22 13D/A INCY / Incyte Corporation 23,762,767 34,389,438
2016-08-15 13D/A GHDX / Genomic Health, Inc. 13,969,039 14,069,039
2016-08-11 13D/A GHDX / Genomic Health, Inc. 13,967,949 13,969,039
2016-05-19 13D/A GHDX / Genomic Health, Inc. 13,967,949
2016-03-17 13D/A INCY / Incyte Corporation 22,898,477 23,762,767
2016-02-16 13D/A INCY / Incyte Corporation 19,759,538 22,898,477
2015-09-18 13D/A INCY / Incyte Corporation 19,759,538
2015-02-17 13G/A BCRX / BioCryst Pharmaceuticals, Inc. 10,713,686
2015-01-09 13D/A GEVA / Synageva Biopharma Corp 11,906,914
2014-06-10 13G/A BCRX / BioCryst Pharmaceuticals, Inc. 10,890,872
2014-05-23 13D/A INCY / Incyte Corporation 19,741,731
2014-04-29 13D/A GEVA / Synageva Biopharma Corp 10,889,414
2014-03-10 13D/A GEVA / Synageva Biopharma Corp 10,837,894
2014-02-25 13G BCRX / BioCryst Pharmaceuticals, Inc. 6,699,979
2013-11-15 13D/A INCY / Incyte Corporation 19,719,314
2013-09-27 13D/A GEVA / Synageva Biopharma Corp
2013-08-02 13D/A BCRX / BioCryst Pharmaceuticals, Inc. 6,699,979
2013-07-11 13D/A SGEN / Seagen Inc 19,512,451
2013-07-11 13D/A GHDX / Genomic Health, Inc. 13,883,142
2013-07-11 13D/A INCY / Incyte Corporation 30,202,598
2013-07-11 13D/A BCRX / BioCryst Pharmaceuticals, Inc. 5,563,615
2013-07-11 13D/A GEVA / Synageva Biopharma Corp 9,407,686
2013-06-05 13D/A GHDX / Genomic Health, Inc. 13,874,589
2013-06-03 13D/A GHDX / Genomic Health, Inc. 13,493,157
2013-05-30 13D/A GHDX / Genomic Health, Inc. 13,313,574
2013-05-24 13D/A GHDX / Genomic Health, Inc. 13,192,308
2013-05-16 13D/A GHDX / Genomic Health, Inc. 13,112,891
2013-05-14 13D/A GHDX / Genomic Health, Inc. 13,041,452
2013-02-21 13D/A GHDX / Genomic Health, Inc. 12,800,669
2013-02-14 13D/A GHDX / Genomic Health, Inc. 12,751,584
2013-01-10 13D/A GEVA / Synageva Biopharma Corp
2012-11-15 13D/A GHDX / Genomic Health, Inc. 12,354,212
2012-10-23 13D/A BCRX / BioCryst Pharmaceuticals, Inc. 5,563,615
2012-07-31 13D/A GHDX / Genomic Health, Inc. 11,426,985
2012-07-20 13D/A GEVA / Synageva Biopharma Corp
2012-07-19 13D/A
2012-06-21 13D/A RDEA / Ardea Biosciences, Inc. 0
2012-06-15 13D/A SGEN / Seagen Inc 19,494,951
2012-06-15 13D/A INCY / Incyte Corporation 28,310,559
2012-05-18 13D/A GHDX / Genomic Health, Inc. 11,259,579
2012-05-04 13D/A GEVA / Synageva Biopharma Corp
2012-04-23 13D/A SGEN / Seagen Inc 21,504,963
2012-04-23 13D/A
2012-04-23 13D/A RDEA / Ardea Biosciences, Inc. 7,163,004
2012-04-23 13D/A GHDX / Genomic Health, Inc. 10,572,931
2012-04-23 13D/A INCY / Incyte Corporation 27,797,636
2012-04-23 13D/A BCRX / BioCryst Pharmaceuticals, Inc. 7,146,948
2012-03-06 13D/A GHDX / Genomic Health, Inc. 10,517,490
2012-02-17 13D/A GHDX / Genomic Health, Inc. 9,805,339
2012-02-06 13D/A RDEA / Ardea Biosciences, Inc. 7,163,004